Article info
PDFOriginal research
Potential candidate for oral pericoital contraception: evaluating ulipristal acetate plus cyclo-oxygenase-2 inhibitor for ovulation disruption
- Correspondence to Dr Erica P Cahill, Obstetrics and Gynecology, Stanford University, Stanford, California, USA; epcahill{at}stanford.edu
Citation
Potential candidate for oral pericoital contraception: evaluating ulipristal acetate plus cyclo-oxygenase-2 inhibitor for ovulation disruption
Publication history
- Received December 21, 2021
- Accepted February 28, 2022
- First published April 25, 2022.
Online issue publication
July 12, 2022
Article Versions
- Previous version (25 April 2022).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.